MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3899/jrheum.190494

Медицинская библиотека · The Journal of rheumatology · 2020

Pilot Study of the Juvenile Dermatomyositis Consensus Treatment Plans: A CARRA Registry Study.

Liu Kuan, Tomlinson George, Reed Ann M, Huber Adam M, Saarela Olli, Bout-Tabaku Sharon M, Curran Megan, Dvergsten Jeffrey A, Eberhard Barbara A, Jung Lawrence K, Kim Susan, Ringold Sarah, Rouster-Steven Kelly A, Tesher Melissa, Wahezi Dawn M, Feldman Brian M, CARRA Registry Investigators

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

To determine the feasibility of comparing the Childhood Arthritis and Rheumatology ResearchAlliance (CARRA) consensus treatment plans (CTP) in treating moderate new-onset juvenile dermatomyositis (JDM) using the CARRA registry, and to establish appropriate analytic methods to control for confounding by indication and missing data.

METHODS

A pilot cohort of 39 patients with JDM from the CARRA registry was studied. Patients were assigned by the treating physician, considering patient/family preferences, to 1 of 3 CTP: methotrexate (MTX) and prednisone (MP); intravenous (IV) methylprednisolone, MTX, and prednisone (MMP); or IV methylprednisolone, MTX, prednisone, and IV immunoglobulin (MMPI). The primary outcome was the proportion of patients achieving moderate improvement at 6 months under each CTP. Statistical methods including multiple imputation and inverse probability of treatment weighting were used to handle missing data and confounding by indication.

RESULTS

Patients received MP (n = 13), MMP (n = 18) and MMPI (n = 8). Patients in all CTP had significant improvement in disease activity. Of the 36 patients who remained in our pilot study at 6 months, 16 (44%) of them successfully achieved moderate improvement at 6 months (6/13, 46% for MP; 7/15, 47% for MMP; 3/8, 38% for MMPI). After correcting for confounding, there were no statistically significant pairwise differences between the CTP (P = 0.328-0.88).

CONCLUSION

We gained valuable experience and insight from our pilot study that can be used to guide the design and analysis of comparative effectiveness studies using the CARRA registry CTP approach. Our analytical methods can be adopted for future comparative effectiveness studies and applied to other rare disease observational studies.

Для цитирования: Liu Kuan, Tomlinson George, Reed Ann M, Huber Adam M, Saarela Olli, Bout-Tabaku Sharon M, Curran Megan, Dvergsten Jeffrey A, Eberhard Barbara A, Jung Lawrence K, Kim Susan, Ringold Sarah, Rouster-Steven Kelly A, Tesher Melissa, Wahezi Dawn M, Feldman Brian M, CARRA Registry Investigators. Pilot Study of the Juvenile Dermatomyositis Consensus Treatment Plans: A CARRA Registry Study.. The Journal of rheumatology. 2020. DOI: 10.3899/jrheum.190494.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.